<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720197</url>
  </required_header>
  <id_info>
    <org_study_id>BETTER</org_study_id>
    <nct_id>NCT03720197</nct_id>
  </id_info>
  <brief_title>Registry of Patients Living With Type 1 Diabetes</brief_title>
  <official_title>Registry of Individuals With Type 1 Diabetes Living in Quebec: The BETTER Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes
      living in the province of Quebec will be established. The objective of this registry will be
      to measure the frequency and the severity of episodes of hypoglycemia. Participants will be
      invited to answer questionnaires about the frequency of their hypoglycemic episodes, their
      fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin
      therapy, nutrition, exercise, etc.), etc.

      Participation to the registry is divided in 3 phases. The first phase is mandatory for all
      participants. Phases 2 and 3 are optional.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of phase 1 is to draw an overall picture of the population with type 1 diabetes
      in Quebec in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes
      complications. It will take you about 10 minutes to answer the questionnaire.

      The objective of phase 2 is to characterize the causes, experience and consequences of
      hypoglycemia.

      The objective of phase 3 is to collect information on diabetes and hypoglycemia treatment,
      hyperglycemia management, sleep habits, depression, physical activity and the benefits of
      technologies to reduce the frequency of hypoglycemia. Phase 3 also involves answering a food
      questionnaire, wearing a step counter, measuring waist circumference and if the participant
      accepts to provide the research team with their latest blood and urine tests as well as their
      list of medications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Number of non-severe hypoglycemic episodes</measure>
    <time_frame>12 months</time_frame>
    <description>Participants will be asked to report the number of non-severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of non-severe hypoglycemia is a blood sugar below 3.0 mmol/L that the participant was able to treat himself</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemic episodes</measure>
    <time_frame>12 months</time_frame>
    <description>Participants will be asked to report the number of severe hypoglycemic episodes in the last 12 months in a questionnaire designed by the investigators. The definition of severe hypoglycemia is low blood sugar levels requiring help from another person or use of glucagon or hospitalization or loss of consciousness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Fear of hypoglycemia will be assessed by the Hypoglycemia Fear Survey II.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes distress</measure>
    <time_frame>1 month</time_frame>
    <description>Diabetes distress will be assessed by the Diabetes Distress Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical follow-up for diabetes</measure>
    <time_frame>12 months</time_frame>
    <description>Participants will be asked to report in a questionnaire designed by the investigators how many times in the last 12 months they have seen a health care professionals (family doctor, medical specialist, nurse, nutritionnist, kinesiologist, psychologist, pharmacist, social worker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin doses</measure>
    <time_frame>3 days</time_frame>
    <description>Participants will be asked to report in a questionnaire designed by the investigators their insulin doses of the last 3 days (basal insulin and insulin given at mealtime).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>1 week</time_frame>
    <description>Physical activity will be assessed by the International Physical Activity Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep habits</measure>
    <time_frame>1 month</time_frame>
    <description>Sleep habits will be assessed by the Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>2 weeks</time_frame>
    <description>Depression will be assessed by the Patient Health Questionnaire (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of steps</measure>
    <time_frame>14 days</time_frame>
    <description>The number of steps will be measured by a pedometer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Participants aged less than 14 years old</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online questionnaire - Phase 1</intervention_name>
    <description>Draw an overall picture of the population with type 1 diabetes in Quebec in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
    <arm_group_label>Participants aged less than 14 years old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online questionnaire - Phase 2</intervention_name>
    <description>Characterize the causes, experience and consequences of hypoglycemia.</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online questionnaire - Phase 3</intervention_name>
    <description>Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food questionnaire</intervention_name>
    <description>24-hour food recall questionnaire</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Podometer</intervention_name>
    <description>Participants will wear a podometer for 14 consecutives days</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Waist circumference</intervention_name>
    <description>Participants will be asked to measure their waist circumference</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and urine tests</intervention_name>
    <description>Participants will be invited to send us their latests blood and urine test results.</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>List of medications</intervention_name>
    <description>Participants will be invited to send us their list of medications</description>
    <arm_group_label>Participants aged 14 years old and older</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with type 1 diabetes living in the province of Quebec.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 1 diabetes

          -  Living in the province of Quebec (Canada)

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Gestational diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Rabasa-Lhoret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Messier</last_name>
    <phone>514-987-5500</phone>
    <phone_ext>3227</phone_ext>
    <email>virginie.messier@ircm.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H7K3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Messier</last_name>
      <phone>514-987-5500</phone>
      <phone_ext>3227</phone_ext>
      <email>virginie.messier@ircm.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Remi Rabasa-Lhoret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remi Rabasa-Lhoret</last_name>
      <phone>514-987-5500</phone>
      <phone_ext>3227</phone_ext>
      <email>remi.rabasa-lhoret@ircm.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Remi Rabasa-Lhoret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Pelletier</last_name>
      <email>catherine.pelletier@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Melanie Henderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Legault</last_name>
      <email>laurent.legault@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Laurent Legault</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaberi Dasgupta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meranda Nakhla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Québec-Université Laval</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Gagnon</last_name>
      <email>claudia.gagnon@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Claudia Gagnon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andre Carpentier</last_name>
      <email>andre.carpentier@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Carpentier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherches Cliniques de Montreal</investigator_affiliation>
    <investigator_full_name>Rémi Rabasa-Lhoret</investigator_full_name>
    <investigator_title>Full professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

